李环球

发布时间：2026-02-10浏览次数：15

  • 1、Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.,J Med Chem. 2025, 68, 14907-14918.,一区top期刊,IF:7.8,通讯作者
  • 2、Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer.,J Med Chem. 2025, 68, 17794-17807.,一区top期刊,IF:7.8,通讯作者
  • 3、Computational Discovery and Repurposing of Chloramphenicol Succinate as a Potent P2Y14 Receptor Antagonist for Inflammatory Bowel Disease Therapy.,J Adv Res. 2025, /doi.org/10.1016/j.jare.2025.08.035. ,一区top期刊IF:13,通讯作者
  • 4、Discovery of Novel P2Y14R Inhibitors for Ameliorating Liver Fibrosis by Suppressing Hepatic Stellate Cell Activation.,J Med Chem. 2025, 68, 23277–23299.,一区top期刊IF:7.8,通讯作者
  • 5、Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors.,Pharmacol Ther 2025, 267, 108802.,一区top期刊IF:12,通讯作者
  • 6、Small-molecule inhibitors in psoriasis: medicinal chemistry insights.,Expert. Opin. Drug. Dis. 2025, 20, 891-912. ,SCI二区,通讯作者
  • 7、Insights of affinity-based probes for target identification in drug discovery. ,Eur J Med Chem 2025, 293, 117711.,二区top期刊,通讯作者
  • 8、Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics. ,J Adv Res 2025, 69, 427-488. ,一区top期刊IF:13,通讯作者
  • 9、Targeting P2Y14R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis.,Nat Commun 2024, 15, 2083. ,一区top期刊 IF:16.6,通讯作者
  • 10、Macrophage P2Y6R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses. ,Acta Pharma Sin B 2024, 14, 4360-4377.,一区top期刊 IF = 14.7,通讯作者
  • 11、Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways.,Eur Heart J 2024, 45, 268–283.,一区top期刊IF:38.8,共同一作
  • 12、Discovery of novel FUT8 inhibitors with promising affinity and in vivo efficacy for colorectal cancer therapy.,Bioorgan Chem 2024, 149, 104492.,二区top,通讯作者
  • 13、Network pharmacology-based analysis of Jin-Si-Wei on the treatment of Alzheimer’s disease.,J Ethnopharmacol 2024, 319, 117291.,二区,通讯作者
  • 14、Recent advances in the development of P2Y14R inhibitors: a patent and literature review (2018-present).,Expert Opin Ther Patents. 2024, 34,611-625 ,二区,通讯作者
  • 15、Prediction of Drug-Induced Liver Injury: From Molecular Physicochemical Properties and Scaffold Architectures to Machine Learning Approaches.,Chem Bio Drug Des 2024,104:e14607,通讯作者
  • 16、Discovery of Selective P2Y6R Antagonists with High-Affinity and In Vivo Efficacy for Inflammatory Diseases Therapy. ,J Med Chem. 2023, 66, 6315-6332.,一区top期刊IF:7.8,通讯作者
  • 17、Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist. ,Phytomedicine. 2023, 115, 154851.,一区top期刊IF:7.9,通讯作者
  • 18、FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer.,Cell Death Dis 2023, 14(8): 495. ,一区top期刊IF:9.8,通讯作者
  • 19、Advances in the therapeutic potential of inhibitors targeting fucosyltransferases in cancer. ,Drug Discov Today 2023, 28, 103394.,一区,通讯作者
  • 20、Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y14R antagonists with anti-gout potential. ,Eur J Med Chem 2022, 227: 113933,一区top期刊,通讯作者